GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Return-on-Tangible-Asset

Evotec SE (Evotec SE) Return-on-Tangible-Asset : -3.32% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Evotec SE's annualized Net Income for the quarter that ended in Dec. 2023 was $-70.4 Mil. Evotec SE's average total tangible assets for the quarter that ended in Dec. 2023 was $2,117.2 Mil. Therefore, Evotec SE's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -3.32%.

The historical rank and industry rank for Evotec SE's Return-on-Tangible-Asset or its related term are showing as below:

EVO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -9   Med: 7.39   Max: 22.78
Current: -3.55

During the past 13 years, Evotec SE's highest Return-on-Tangible-Asset was 22.78%. The lowest was -9.00%. And the median was 7.39%.

EVO's Return-on-Tangible-Asset is ranked worse than
62.7% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.84 vs EVO: -3.55

Evotec SE Return-on-Tangible-Asset Historical Data

The historical data trend for Evotec SE's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Return-on-Tangible-Asset Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.12 0.68 13.69 -8.71 -4.34

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.22 -5.74 -3.04 -7.79 -3.32

Competitive Comparison of Evotec SE's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Evotec SE's Return-on-Tangible-Asset falls into.



Evotec SE Return-on-Tangible-Asset Calculation

Evotec SE's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-91.508/( (2074.797+2138.909)/ 2 )
=-91.508/2106.853
=-4.34 %

Evotec SE's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-70.364/( (2095.469+2138.909)/ 2 )
=-70.364/2117.189
=-3.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Evotec SE  (NAS:EVO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Evotec SE Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Evotec SE's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (Evotec SE) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.